Stock Scorecard
Stock Summary for MyMD Pharmaceuticals Inc (MYMD) - $3.30 as of 5/2/2024 4:56:30 PM EST
Total Score
12 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MYMD
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MYMD
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MYMD
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for MYMD
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for MYMD
Financial Details for MYMD
Company Overview |
|
---|---|
Ticker | MYMD |
Company Name | MyMD Pharmaceuticals Inc |
Country | USA |
Description | MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is dedicated to the development of pharmaceutical products targeting aging and age-related diseases; Autoimmune diseases; and chronic pain, anxiety, and sleep disorders. The company is headquartered in Tampa, Florida. |
Sector Name | LIFE SCIENCES |
Industry Name | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
Most Recent Quarter | 3/31/2024 |
Next Earnings Date | 5/13/2024 |
Stock Price History |
|
Last Day Price | 3.30 |
Last Day Price Updated | 5/2/2024 4:56:30 PM EST |
Last Day Volume | 134,894 |
Average Daily Volume | 428,257 |
52-Week High | 70.50 |
52-Week Low | 2.00 |
Last Price to 52 Week Low | 65.00% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 226.64 |
Sector PE | 54.22 |
5-Year Average PE | -0.85 |
Free Cash Flow Ratio | 1.45 |
Industry Free Cash Flow Ratio | 35.91 |
Sector Free Cash Flow Ratio | 32.33 |
Current Ratio Most Recent Quarter | 1.17 |
Total Cash Per Share | 2.28 |
Book Value Per Share Most Recent Quarter | 6.05 |
Price to Book Ratio | 0.42 |
Industry Price to Book Ratio | 11.27 |
Sector Price to Book Ratio | 22.23 |
Price to Sales Ratio Twelve Trailing Months | 0.00 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.80 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.15 |
Share Statistics |
|
Total Shares Outstanding | 2,157,600 |
Market Capitalization | 7,120,080 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 73.68% |
Reported EPS 12 Trailing Months | -5.33 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -3.03 |
Net Income Twelve Trailing Months | -3,999,950 |
Net Income Past Year | -3,999,950 |
Net Income Prior Year | -15,197,336 |
Quarterly Revenue Growth YOY | 0.00% |
5-Year Revenue Growth | -63.75% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 4,923,116 |
Total Cash Past Year | 4,923,116 |
Total Cash Prior Year | 4,835,992 |
Net Cash Position Most Recent Quarter | 4,923,116 |
Net Cash Position Past Year | 1,318,532 |
Long Term Debt Past Year | 3,604,584 |
Long Term Debt Prior Year | 3,604,584 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 0.77 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 12,369,572 |
Total Stockholder Equity Prior Year | 14,695,056 |
Total Stockholder Equity Most Recent Quarter | 12,369,572 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.11 |
MACD Signal | -0.20 |
20-Day Bollinger Lower Band | 0.68 |
20-Day Bollinger Middle Band | 4.17 |
20-Day Bollinger Upper Band | 7.66 |
Beta | 3.17 |
RSI | 53.73 |
50-Day SMA | 20.21 |
200-Day SMA | 109.01 |
System |
|
Modified | 5/2/2024 6:14:59 AM EST |